EP0544838A4 - Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines - Google Patents

Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines

Info

Publication number
EP0544838A4
EP0544838A4 EP91920080A EP91920080A EP0544838A4 EP 0544838 A4 EP0544838 A4 EP 0544838A4 EP 91920080 A EP91920080 A EP 91920080A EP 91920080 A EP91920080 A EP 91920080A EP 0544838 A4 EP0544838 A4 EP 0544838A4
Authority
EP
European Patent Office
Prior art keywords
sequence
vaccines
nanbv
hutch
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91920080A
Other versions
EP0544838A1 (en
Inventor
Suzanne Zebedee
Genevieve Inchauspe
Marc S Nasoff
Alfred M Prince
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HELTING, TORSTEN B.
New York Blood Center Inc
Original Assignee
Pharmacia Genetic Engineering Inc
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27416160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0544838(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Genetic Engineering Inc, New York Blood Center Inc filed Critical Pharmacia Genetic Engineering Inc
Priority to EP02006640A priority Critical patent/EP1227323B2/en
Publication of EP0544838A1 publication Critical patent/EP0544838A1/en
Publication of EP0544838A4 publication Critical patent/EP0544838A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sequence (I) comprises (a) the Hutch c59 DNA sequence shown in SEQ ID NO:46 of the spec; (b) degenerate sequences of the sequence of (a); (c) a mutant variant of the NANBV Hutch c59 strain with the same immunological properties and hybridising to the sequences of (a) and (b); and (d) a DNA sequence which hybridises to the sequences of (a) and (b) and represents a NANBV strain with the same immunological properties as the Hutch subgroup. Also new are:- (i) a 10-200 nucleotide portion of (I) with at least 1 nucleotide difference in sequence from NANBV strain HCV-1, HCV-BK, HCV-J, HC-J2, HC-J4, JCV-JH or JCV-Hh. The difference is silent mutation or causes a change of at least 1 aminoacid; etc.
EP91920080A 1990-08-25 1991-08-23 Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines Withdrawn EP0544838A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02006640A EP1227323B2 (en) 1990-08-25 1991-08-23 Non-A, non-B hepatitis virus antigen, and diagnostic methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57364390A 1990-08-25 1990-08-25
US573643 1990-08-27
US61636990A 1990-11-21 1990-11-21
US616369 1990-11-21
US74856491A 1991-08-21 1991-08-21
US748564 1991-08-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP02006640A Division EP1227323B2 (en) 1990-08-25 1991-08-23 Non-A, non-B hepatitis virus antigen, and diagnostic methods

Publications (2)

Publication Number Publication Date
EP0544838A1 EP0544838A1 (en) 1993-06-09
EP0544838A4 true EP0544838A4 (en) 1997-09-10

Family

ID=27416160

Family Applications (2)

Application Number Title Priority Date Filing Date
EP91920080A Withdrawn EP0544838A4 (en) 1990-08-25 1991-08-23 Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines
EP02006640A Expired - Lifetime EP1227323B2 (en) 1990-08-25 1991-08-23 Non-A, non-B hepatitis virus antigen, and diagnostic methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02006640A Expired - Lifetime EP1227323B2 (en) 1990-08-25 1991-08-23 Non-A, non-B hepatitis virus antigen, and diagnostic methods

Country Status (9)

Country Link
EP (2) EP0544838A4 (en)
KR (1) KR930702365A (en)
AT (1) ATE346302T1 (en)
AU (1) AU673135B2 (en)
CA (1) CA2090335A1 (en)
DE (1) DE69133552C5 (en)
DK (1) DK1227323T4 (en)
ES (1) ES2273934T5 (en)
WO (1) WO1992003458A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0489968T3 (en) * 1990-12-14 1997-03-24 Innogenetics Nv Synthetic antigens for detection of antibodies against hepatitis C virus
WO1992022655A1 (en) 1991-06-10 1992-12-23 Lucky Limited Hepatitis c diagnostics and vaccines
JP3516681B2 (en) 1991-06-24 2004-04-05 カイロン コーポレイション Hepatitis C virus (HCV) polypeptide
PT787807E (en) * 1991-08-27 2003-08-29 Hoffmann La Roche INITIATORS AND PROBES FOR HEPATITIS C DETECTION
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
DE4240980A1 (en) * 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh HCV peptide antigens and method for the determination of HCV
US6153378A (en) * 1992-10-16 2000-11-28 Bionova Corporation Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus
WO1994021816A1 (en) * 1993-03-25 1994-09-29 Envirocon International Incorporated Test kits and methods for rapidly testing for contamination by microorganisms
GB9507232D0 (en) * 1995-04-07 1995-05-31 Gatsby Charitable Foundation Plant pathogen resistance genes and uses thereof
CN1061991C (en) * 1994-06-08 2001-02-14 北京医科大学 Schistosome vaccine peptide NO.3
CN1068334C (en) * 1994-06-08 2001-07-11 北京医科大学 Schistosome vaccine peptide No.2
CN1061990C (en) * 1994-06-08 2001-02-14 北京医科大学 Schistosome vaccine peptide No.1
JP2005533855A (en) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト An antigen encoded by another reading frame from a pathogenic virus.
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
WO2004084938A1 (en) 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
TWI358301B (en) 2003-07-11 2012-02-21 Intercell Ag Hcv vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293274A1 (en) * 1987-03-31 1988-11-30 Mitsubishi Kasei Corporation DNA molecules encoding non-A, non-B hepatitis antigens, and their use in producing said antigens
WO1990002206A1 (en) * 1988-08-24 1990-03-08 The United States Of America, Represented By The Secretary, United States Department Of Commerce Detection of non-a, non-b hepatitis
EP0363025A2 (en) * 1988-09-30 1990-04-11 The Research Foundation for Microbial Diseases of Osaka University Non-A, non-B hepatitis virus antigen peptide
EP0377303A1 (en) * 1988-12-21 1990-07-11 Immuno Japan Inc. Non-A, non-B hepatitis virus genome RNA, cDNA and virus antigen protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744242A1 (en) * 1987-02-20 1989-07-06 Seelig Renate VIRUSANT, METHOD FOR ITS OBTAINMENT AND USE IN DIAGNOSIS AND THERAPY (VACCINE)
AU624105B2 (en) * 1987-11-18 1992-06-04 Novartis Vaccines And Diagnostics, Inc. Nanbv diagnostics and vaccines
CN1049686C (en) * 1987-11-18 2000-02-23 希龙股份有限公司 Nanbv diagnostics and vaccines
JPH04501203A (en) * 1988-07-06 1992-03-05 ジェネラブズ　インコーポレイティド Post-transfusion-borne, non-A, non-B hepatitis viruses and antigens
JP2656995B2 (en) * 1989-03-17 1997-09-24 カイロン コーポレイション NANBV diagnostics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293274A1 (en) * 1987-03-31 1988-11-30 Mitsubishi Kasei Corporation DNA molecules encoding non-A, non-B hepatitis antigens, and their use in producing said antigens
WO1990002206A1 (en) * 1988-08-24 1990-03-08 The United States Of America, Represented By The Secretary, United States Department Of Commerce Detection of non-a, non-b hepatitis
EP0363025A2 (en) * 1988-09-30 1990-04-11 The Research Foundation for Microbial Diseases of Osaka University Non-A, non-B hepatitis virus antigen peptide
EP0377303A1 (en) * 1988-12-21 1990-07-11 Immuno Japan Inc. Non-A, non-B hepatitis virus genome RNA, cDNA and virus antigen protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MILLER R H ET AL: "HEPATITIS C VIRUS SHARES AMINO ACID SEQUENCE SIMILARITY WITH PESTIVIRUSES AND FLAVIVIRUSES AS WELL AS MEMBERS OF TWO PLANT VIRUS SUPERGROUPS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 6, 1 March 1990 (1990-03-01), pages 2057 - 2061, XP000310581 *
NASOFF M S ET AL: "Identification of an immunodominant epitope within the capsid protein of hepatitis C virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 88, no. 12, 15 June 1991 (1991-06-15), pages 5462 - 5466, XP000310531 *
OKAMOTO H. ET AL.: "The 5'-terminal sequence of the hepatitis C virus genome", JAPANESE JOURNAL OF EXPERIMENTAL MEDECINE, vol. 60, no. 3, June 1990 (1990-06-01), pages 163 - 177, XP002034219 *

Also Published As

Publication number Publication date
DK1227323T3 (en) 2007-03-26
AU8904191A (en) 1992-03-17
CA2090335A1 (en) 1992-02-26
EP1227323A1 (en) 2002-07-31
AU673135B2 (en) 1996-10-31
EP1227323B2 (en) 2011-01-19
EP1227323B1 (en) 2006-11-22
KR930702365A (en) 1993-09-08
ATE346302T1 (en) 2006-12-15
WO1992003458A1 (en) 1992-03-05
ES2273934T5 (en) 2011-05-17
DE69133552C5 (en) 2008-01-10
DE69133552D1 (en) 2007-01-04
DE69133552T2 (en) 2007-08-23
DK1227323T4 (en) 2011-04-26
EP0544838A1 (en) 1993-06-09
ES2273934T3 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
EP0544838A4 (en) Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines
EP0992580B1 (en) Immunodominant human T-cell epitopes of Hepatitis C virus
Nishizawa et al. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology
Battegay et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2. 1 molecules
Martell et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation
MY110260A (en) Nanbv diagnostics and vaccines.
ATE195953T1 (en) PEPTIDES FOR INDUCING IMMUNE RESPONSE BY CYTOTOXIC T LYMPHOCYTES AGAINST HEPATITIS C VIRUS
Kurokohchi et al. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region
CA2389206A1 (en) Activation of hcv-specific t cells
Matsuura et al. The molecular biology of hepatitis C virus
EP0644894A1 (en) Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus.
CA2505942A1 (en) West nile virus vaccine
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
CA2045323A1 (en) Non-a, non-b hepatitis virus genomic cdna and antigen polypeptide
Okamoto et al. Full-length nucleotide sequence of a Japanese hepatitis C virus isolate (HC-J1) with high homology to USA isolates.
WO2001021807A1 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
US5789544A (en) Method for producing ectoprotein of hepatitis C virus
WO1995032290A3 (en) Non-a/non-b/non-c/non-d/non-e hepatitis agents and molecular cloning thereof
Honda et al. Sequence comparisons for a hepatitis C virus genome RNA isolated from a patient with liver cirrhosis
ZA914682B (en) Non-a non-b sequences
RU2004104357A (en) VACCINE COMPOSITION POTENTIATED BY COMBINATION OF DNA AND ANTIGEN
KR950000880A (en) Total Nucleotide Sequences and Amino Acid Sequences Inferred from KHCV-L2, a Type of Korean Hepatitis C Virus
Gagneten et al. 25 Hepatitis C vaccines
MY105097A (en) Nanbv diagnostics and vaccines
NO950527L (en) Analogous Procedure for Preparation of Non-A, Non-B Hepatitis Virus Antigen Peptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970721

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 20000828

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HELTING, TORSTEN B.

Owner name: NEW YORK BLOOD CENTER, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020329